These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28852974)

  • 1. Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis.
    Roviello G; Corona SP; Generali D
    Med Oncol; 2017 Aug; 34(10):166. PubMed ID: 28852974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome.
    Colomba E; Marret G; Baciarello G; Lavaud P; Massard C; Loriot Y; Albiges L; Carton E; Alexandre J; Huillard O; Culine S; Fizazi K
    Eur J Cancer; 2020 Apr; 129():117-122. PubMed ID: 32151941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials.
    Roviello G; Sigala S; Danesi R; Re MD; Bonetta A; Cappelletti MR; Zanotti L; Bottini A; Generali D
    Crit Rev Oncol Hematol; 2016 May; 101():12-20. PubMed ID: 26971992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between RCT methodology and disease indication with mineralocorticoid-related toxicity for patients receiving abiraterone acetate for advanced prostate cancer: A meta-analysis of RCTs.
    Hall ME; Padgett WJ; Klaassen Z; Magee DE; Luckenbaugh AN; Laviana AA; Satkunasivam R; Schaffer K; Wallis CJD
    Clin Genitourin Cancer; 2023 Oct; 21(5):e370-e377. PubMed ID: 37236862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis.
    Zhu J; Liao R; Su C; Liang D; Wu J; Qiu K; Li J
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):193-198. PubMed ID: 29257709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
    Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
    J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
    Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B
    Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Corticosteroids in the management of advanced prostate cancer].
    Kübler H
    Urologe A; 2017 Feb; 56(2):217-223. PubMed ID: 27878318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Abiraterone Acetate Administration in Elderly Patients Receiving Peritoneal Dialysis with Castration-Resistant Prostate Cancer: Two Case Reports.
    Kimata R; Tomita Y; Kondo Y
    J Nippon Med Sch; 2019; 86(2):135-138. PubMed ID: 31130566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
    Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS
    Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors.
    Procopio G; Grassi P; Testa I; Verzoni E; Torri V; Salvioni R; Valdagni R; de Braud F
    Am J Clin Oncol; 2015 Oct; 38(5):479-82. PubMed ID: 24064757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.
    Jamani R; Lee EK; Berry SR; Saluja R; DeAngelis C; Giotis A; Emmenegger U
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1391-1399. PubMed ID: 27561266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ascending Flaccid Paralysis Secondary to Hypokalemia in A Cancer Patient using Abiraterone - A Case Report.
    de Almeida DCB; Costa AL; de Oliveira Faria BL; de Carvalho FB; Cintra MTG
    Curr Drug Saf; 2023; 18(1):107-111. PubMed ID: 35469572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic].
    Rozet F; Mongiat-Artus P; Ploussard G; Rouprêt M; Cacoub P; Fournier G; Mathieu R
    Prog Urol; 2021 Apr; 31(5):243-244. PubMed ID: 33468416
    [No Abstract]   [Full Text] [Related]  

  • 18. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.
    Agarwal N; Hutson TE; Vogelzang NJ; Sonpavde G
    Future Oncol; 2010 May; 6(5):665-79. PubMed ID: 20465382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A Case of Fulminant Hepatitis after Administration of Abiraterone Acetate].
    Yumiba S; Komori K; Iwanishi T; Koida Y; Kobayashi M; Ono Y
    Hinyokika Kiyo; 2017 Nov; 63(11):479-482. PubMed ID: 29232800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.